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Introduction
Carcinoma of the breast is a histologically heterogeneous
disease. Invasive lobular carcinoma (ILC) accounts for
8–14% of all breast cancers [1,2]. Data from a recent epi-
demiologic study [3] indicate that for unknown causes the
incidence of this type of breast cancer is increasing, espe-
cially among postmenopausal women.
The morphologic features of lobular carcinoma differ from
those of ductal carcinoma. ILC is characterized by small,
round cells that are bland in appearance and have scant
cytoplasm, which infiltrate the stroma in single file and sur-
round benign breast tissues in a targeted manner [1,4].
Infiltration typically does not destroy anatomic structures
or incite a substantial connective tissue response. By
virtue of their distinctive growth pattern and biology,
lobular carcinomas often fail to form distinct masses that
can easily be diagnosed by palpation or mammography.
This can make early diagnosis challenging [5,6] and
breast conservation approaches more difficult. Lobular
carcinomas may have a substantially increased propensity
for multifocal and multicentric distribution and for bilateral-
ity [5,7–11]. Metastatic spread with an uncommon pattern
of involvement has been reported [12,13].
CNS = central nervous system; DFS = disease-free survival; EGFR = epidermal growth factor receptor; ER = estrogen receptor; IDC = infiltrating
ductal carcinoma; ILC = infiltrating lobular carcinoma; OS = overall survival; PgR = progesterone receptor.
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Abstract
Introduction: Invasive lobular carcinoma (ILC) comprises
approximately 10% of breast cancers and appears to have a
distinct biology. Because it is less common than infiltrating
ductal carcinoma (IDC), few data have been reported that
address the biologic features of ILC in the context of their
clinical outcome. In the present study we undertook an
extensive comparison of ILC and IDC using a large database to
provide a more complete and reliable assessment of their
biologic phenotypes and clinical behaviors.
Methods: The clinical and biological features of 4140 patients
with ILC were compared with those of 45,169 patients with
IDC (not otherwise specified). The median follow-up period
was 87 months.
Results: In comparison with IDC, ILC was significantly more
likely to occur in older patients, to be larger in size, to be
estrogen and progesterone receptor positive, to have lower
S-phase fraction, to be diploid, and to be HER-2, p53, and
epidermal growth factor receptor negative. It was more
common for ILC than for IDC to metastasize to the
gastrointestinal tract and ovary. The incidence of contralateral
breast cancer was higher for ILC patients than for IDC patients
(20.9% versus 11.2%; P < 0.0001). Breast preservation was
modestly less frequent in ILC patients than in IDC patients. The
5-year disease-free survival was 85.7% for ILC and 83.5% for
IDC (P = 0.13). The 5-year overall survival was 85.6% for ILC
and 84.1% for IDC (P = 0.64).
Conclusion: Despite the fact that the biologic phenotype of
ILC is quite favorable, these patients do not have better clinical
outcomes than do patients with IDC. At present, management
decisions should be based on individual patient and tumor
biologic characteristics, and not on lobular histology.
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Because it is substantially less common than infiltrating
ductal carcinoma (IDC), knowledge about the clinical
outcome of lobular carcinoma has been based on studies
including relatively small numbers of patients. Reported
prognosis varies and has been reported to be worse
[14,15], no different [16–19], or better [20] than that with
IDC. This reported variability might be due to relatively
small numbers of cases in each analysis. In addition, few
data have been reported on the biologic features of
lobular carcinomas within the context of their clinical
outcome. We therefore undertook an extensive compari-
son of ILC and IDC using a large database to provide a
more complete and reliable assessment of their biologic
phenotypes and clinical behaviors, which might yield infor-
mation useful for clinical decision making or for further
exploring the biologic nature of this disease.
Methods
Study population
The Breast Center at Baylor College of Medicine maintains
databases of breast cancer patients whose biopsy or
mastectomy specimens were sent to central laboratories
for steroid receptor assays. These patients were diagnosed
and treated at more than 370 academic and community
institutions throughout the USA. The central laboratories
were located at the University of Texas Health Science
Center at San Antonio and at Nichols Institute in San Juan
Capistrano, California. Histologic diagnoses were made
by pathologists at community hospitals and were not
reviewed centrally. ILC was not further subtyped in these
databases, and patients with mixed ILC and IDC were
excluded. Follow-up information was obtained from tumor
registries, by direct review of medical records conducted by
data managers, or by data collection forms completed at the
office of the referring physicians. These databases contain
information on 50,399 patients with early breast cancer who
were diagnosed between 1970 and 1998. Among them,
4140 (8.2%) were diagnosed as having ILC and 45,169
(89.6%) as having IDC. Patients with special histologic types
(tubular, mucinous, and medullary) were excluded, as were
those with gross distant metastases at diagnosis. Histologic
grade was not analyzed in the present study because in
most cases this information was not available.
The patient information contained in this report was
obtained from two data repositories maintained by the
Breast Center at Baylor College of Medicine. Each reposi-
tory has been reviewed by Institutional Review Boards at
the University of Texas Health Science Center at San
Antonio and at Baylor College of Medicine.
Prognostic factors
Estrogen receptor (ER) levels were measured using the
dextran-coated charcoal method as previously described
[21]. From 1970 to 1984, [3H]estradiol was used as a
labeled ligand. During the same period, progesterone
receptor (PgR) levels were measured by sucrose density
gradient [22]. In 1985, the standard multipoint dextran-
coated charcoal assay was modified to incorporate
[125I]estradiol and [3H]R5020 in a single assay, allowing
simultaneous determination of levels of both ER and PgR
[23]. Levels of 3 fmol/mg protein or greater were consid-
ered positive for ER, and levels of 5 fmol/mg protein or
greater were considered positive for PgR. DNA ploidy and
S-phase fraction were evaluated using flow cytometry, as
previously described [24–26]. S-phase fractions below
6% were considered low, those in the range 6–10% were
considered intermediate, and those in excess of 10%
were considered high. HER-2 status was determined
using Western blotting [27]. The cutoff value between low
and high HER-2 expression was 1 U/µg protein. Epider-
mal growth factor receptor (EGFR) levels were measured
by radiobinding assay, using fixed concentrations of radio-
labeled EGF and varying concentrations of unlabeled
EGF. Levels of 10 fmol/mg or greater were considered
positive. This cutoff has been in use at the Nichols Insti-
tute since 1992 and its use is in accordance with pub-
lished studies [28,29]. p53 status was determined by
immunohistochemistry, and negative nuclear staining was
a surrogate marker for normal p53 [30].
Statistical methods
Descriptive statistics are reported as frequencies or
medians. The clinical and biologic characteristics of
lobular and ductal carcinoma were compared using con-
tingency tables, χ2 tests and Fisher’s exact tests.
Overall survival (OS) was defined as the interval between the
diagnostic biopsy and death from any cause, death being
scored as an event, and patients who were still alive were
censored at the time of last follow-up. OS after first recur-
rence was calculated from the date of first recurrence, death
being scored as an event, and patients who were still alive
were censored at the time of last follow-up. Disease-free sur-
vival (DFS) was also calculated from the date of first diag-
nostic biopsy, with first recurrences, local or distant, being
scored as an event, and with censoring of other patients at
the time of last follow-up or death. Local recurrence was
defined as tumor arising in the treated breast, chest wall or
axilla. OS and DFS curves were drawn using Kaplan–Meier
estimates, and were compared using log rank tests. Survival
rates are presented with their 95% confidence intervals.
Multivariate analyses of DFS and OS, with stepwise vari-
ables selection, were conducted using Cox proportional
hazard regression models. Analyses were performed using
SAS Version 8.00 (SAS Institute Inc., Cary, NC, USA).
Results
Patient and tumor characteristics
From a total of 50,399 patients with early breast cancer
in the Baylor College of Medicine Breast Cancer data-R151
bases, we identified 4140 patients (8.2%) with ILC and
45,169 (89.6%) patients with IDC (not otherwise speci-
fied). The median follow-up time was 87 months (range
0–254 months).
Table 1 summarizes the clinical and biologic tumor charac-
teristics according to histologic type. The median ages of
patients with ILC and IDC were 64.6 and 60.6 years,
respectively. ILCs were slightly larger on average (53.8%
larger than 2 cm) than IDCs (48.6% larger than 2 cm;
P < 0.0001). More revealing, however, was a 50% greater
chance of ILC presenting as a large tumor, with 14.0% of
ILCs exceeding 5 cm as compared with 9.1% of IDCs.
Despite this difference in tumor size, there was no differ-
ence in the frequency of axillary node involvement.
Despite the larger tumor size, ILCs had more favorable
biologic characteristics (Table 1). The proportion of ER-
positive tumors was 92.7% for ILC and 81.2% for IDC
(P < 0.0001). PgR was expressed in 67.4% of ILCs and in
60.2% of IDCs (P < 0.0001). Compared with IDCs, ILCs
were much more likely to be diploid (69.8% of ILCs versus
43.6% of IDCs; P < 0.0001), have a low or intermediate
S-phase fraction (87.8% of ILCs versus 68.6% of IDCs;
P < 0.0001), have normal p53 status (74.4% of ILCs
versus 46.5% of IDCs; P < 0.0001), and be negative for
EGFR (94.1% of ILCs versus 80.7% of IDCs;
P < 0.0001) and HER-2 (89.34% of ILCs versus 75.6%
of IDCs; P < 0.0001). Thus, in comparison with IDC, ILC
was more likely to occur in older patients, to be larger in
size, to be ER and PgR positive, to have a lower S-phase
fraction, to be diploid, and to be negative for HER-2, p53
and EGFR.
The pattern of metastatic dissemination in ILC and IDC
was also different (Table 2). Lung and pleura involvement
was more frequently observed with IDCs (P = 0.0019), as
was involvement of distant nodes (P = 0.018) and of the
central nervous system (CNS; P = 0.0032). The detail of
coding in the database was not sufficient to permit further
distinction between brain, spinal cord, and meningeal
metastases, and therefore the incidence of leptomeningeal
disease could not be determined. ILC was three times
more likely to metastasize to the peritoneum, gastrointesti-
nal tract, and ovaries (6.7% versus 1.8%). Information on
contralateral breast tumors was also available on the
subset of 2855 patients in whom sites of breast cancer
distant from the primary could be assessed. Contralateral
breast cancers in this group were more frequent among
those with ILC (20.9%) than among those with IDC
(11.2%; P < 0.0001; data not shown).
Both local and systemic therapy for breast cancer differed
according to histologic type (Table 3). Patients with ILC
were slightly less likely to undergo lumpectomy (9.5% of
patients with ILC versus 12.7% of patients with IDC;
P < 0.0001). Probably because of the higher hormone
receptor content, adjuvant endocrine therapy was more
frequently given to patients with ILC (28.8%) than to those
with IDC (22.9%; P < 0.0001). On the other hand, the
number of patients with ILC who received adjuvant
chemotherapy was significantly lower (16.2% in ILC
patients versus 23.7% in IDC patients; P < 0.0001).
Disease-free and overall survival
A trend toward better DFS was observed for ILC patients.
The 5-year DFS was 85.7% for patients with ILC and
83.5% for those with IDC (P = 0.13). This modest differ-
ence is not clinically or biologically significant. However,
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Table 1
Patients and tumor biological characteristics by histologic
group
ILC IDC P
Patients (n) 4140 45169
Tumor size
Number with data 3962 43827
≤2 cm (%) 46.1 51.3
>2 and ≤5 cm (%) 39.8 39.5 <0.0001
>5 cm (%) 14.0 9.1
Age
Number with data 3501 38436
≤50 years 19.4 27.8
<0.0001 >50 years 80.6 72.2
Positive lymph nodes
Number with data 3891 43066
0 57.3 58.0
NS ≥1 42.7 42.0
Estrogen receptor
Number tested 4140 45169
Positive (%) 92.7 81.2 <0.0001
Progesterone receptor
Number tested 4075 44307
Positive (%) 67.4 60.2 <0.0001
Ploidy
Number tested 3763 40123
Diploid (%) 69.8 43.6 <0.0001
S-phase fraction
Number tested 3339 34620
Low 68.6 46.7
Intermediate 19.2 21.9 <0.0001
High 12.2 31.4
p53
Number tested 86 1009
Negative (normal; %) 74.4 46.5 <0.0001
HER-2
Number tested 263 2909
Negative (%) 89.3 75.6 <0.0001
Epidermal growth factor receptor
Number tested 203 2366
Negative (%) 94.1 80.7 <0.0001
IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.although ILC patients experienced recurrence less fre-
quently than did IDC patients during the first few years
after diagnosis, the two DFS curves converged after
longer follow-up (Fig. 1a). Despite having more favorable
biologic characteristics, the 5-year OS was not better for
ILC (85.6%) than for IDC (84.1%; P = 0.64; Fig. 1b). For
node-negative patients, DFS and OS were very similar for
the two histologic types.
The median survival after the first recurrence was slightly
longer for ILC patients (22 months, range 0–115 months)
than for IDC patients (19 months, range 0–119 months;
P = 0.002), and the 5-year survival after the first recur-
rence was 32.8% for patients with ILC as compared with
26.7% for patients with IDC (Fig. 2).
Multivariate analyses
Multivariate analyses were performed using Cox regres-
sion models to determine whether ILC was an indepen-
dent prognostic factor for recurrence and death (Table 4).
Factors included in these analyses were tumor size,
number of involved nodes, age, ER status, PgR status,
DNA ploidy, S-phase, and histologic type. Data were avail-
able for all of these variables in 33,860 patients. From
these variables, the factors that remained independently
associated with recurrence, as well as with survival, were
Breast Cancer Research    Vol 6 No 3 Arpino et al.
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Figure 1
(a) The 5-year disease-free survival (DFS) was 85.7% (95% confidence interval [CI] 84.4–87.1%) for invasive lobular carcinoma (ILC) versus
83.5% (95% CI 83.1–84.0%) for invasive ductal carcinoma (IDC; P = 0.13). (b) The 5-year overall survival (OS) was 85.6% (95% CI
84.2–87.0%) for ILC and 84.1% (95% CI 83.7–84.6%) for IDC (P = 0.64).
Table 2
Distant sites of first recurrence
ILC IDC 
Sites (n = 179; %) (n = 2576; %) P
Lungs/pleura 9.0 17.6 0.0019
CNS 1.7 5.3 0.032
Ovary 2.2 0.7 0.0003
Gastrointestinal tracta 4.5 1.1 0.009
Nodes 15.5 22.0 0.018
Bone 34.6 35.5 NS
Skinb 31.8 27.3 NS
Liver 7.3 10.9 NS
Pituitary 0.5 0.1 NS
Percentages do not add up to 100% because of multiple metastatic
sites in the same patient and infrequent or unknown sites not shown.
aStomach, small bowel, colon, appendix, duodenum, and peritoneum.
bSoft tissue and skin. 
CNS, central nervous system; IDC, invasive ductal carcinoma; ILC,
invasive lobular carcinoma; NS, not significant.
Table 3
Local and systemic adjuvant therapy by histologic type
Histologic type
Therapy ILC IDC P
Surgery
Number of patients 4197 45995
None (%) 1.1 0.8
Modified radical mastectomy (%) 89.4 86.5 <0.0001
Lumpectomy (%) 9.5 12.7
Adjuvant therapy
Number of patients 2817 31043
None (%) 42.4 42.3
Chemotherapy (%) 16.2 23.7
<0.0001 Endocrine therapy (%) 28.8 22.9
Chemotherapy and endocrine  12.6 11.1
therapy (%)
IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.as follows: lymph node status, tumor size, age, S-phase,
PgR status, and ER status. Once adjustment based on
these six parameters was made, histologic type did not
emerge as an important prognostic factor. Thus, the lack
of prognostic significance related to ILC versus IDC in uni-
variate analyses is confirmed by the results of the multivari-
ate analyses.
In addition, to determine whether traditional prognostic
factors for IDC would be of value in patients with ILC, a
second set of multivariate analyses of DFS and OS were
performed only in patients with ILC (Table 5). For DFS,
lymph node status, tumor size, S-phase, PgR status, and
DNA ploidy retained their independent prognostic value.
For OS, nodal status, age, tumor size, ER status, and S-
phase were independent prognostic factors.
Discussion
The present study demonstrates that ILC has distinctive
clinical and biologic characteristics compared with IDC.
Lobular carcinomas were more likely to occur in older
patients; to be larger in size, ER and PgR positive, and
diploid with a low S-phase fraction; and to have normal
p53 status and low to absent EGFR and HER-2. The dis-
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Table 4
Multivariate Cox regression models for disease-free survival
and overall survival in patients with invasive ductal carcinoma
and patients with invasive lobular carcinoma
DFS OS
Parameter RR (95% CI) P RR (95% CI) P
Nodes
0 1 <0.0001 1 <0.0001
1–3 1.8 (1.6–1.9) 1.4 (1.3–1.5)
>3 3.4 (3.1–3.6) 2.4 (2.2–2.5)
Tumor size (cm)
≤2 1 <0.0001 1 <0.0001
2–5 1.5 (1.4–1.6) 1.4 (1.3–1.5)
>5 1.9 (1.7–2.1) 2.0 (1.8–2.1)
Age (years)
≤50 1 0.0005 1 <0.0001
>50 1.1 (1.0–1.2) 1.9 (1.7–2.0)
S-phase
Low 1 <0.0001 1 <0.0001
Intermediate 1.4 (1.3–1.5) 1.3 (1.2–1.3)
High 1.5 (1.4–1.7) 1.4 (1.3–1.5)
PgR
Positive 1 <0.0001 1 0.0014
Negative 1.3 (1.2–1.4) 1.3 (1.2–1.4)
ER
Positive 1 0.0017 1 0.048
Negative 1.1 (1.0–1.2) 1.1 (1.0–1.2)
CI, confidence interval; DFS, disease-free survival; ER, estrogen
receptor; OS, overall survival; PgR, progesterone receptor; RR, relative
risk.
Table 5
Multivariate Cox regression models for disease-free survival
and overall survival in invasive lobular carcinoma patients
DFS OS
Parameter RR (95% CI) P RR (95% CI) P
Nodes
0 1 <0.0001 1 <0.0001
1–3 2.2 (1.6–3.2) 1.4 (1.1–1.9)
>3 4.1 (2.9–5.7) 2.2 (1.7–2.9)
Tumor size (cm)
≤2 1 <0.0001 1 <0.0001
>2 1.9 (1.4–2.6) 1.6 (1.3–2.1)
Age (years)
≤50 – NS 1 <0.0001
>50 – 2.3 (1.7–3.1)
S-phase
Low 1 0.002 1 <0.0293
Intermediate 1.7 (1.3–2.2) 1.3 (1.0–1.6)
–high
PgR
Positive 1 0.003 – NS
Negative 1.5 (1.1–1.9) –
ER
Positive – NS 1 0.0006
Negative – 1.9 (1.3–2.8)
Ploidy
Diploid 1 0.03 – NS
Aneuploid 1.7 (1.3–2.2) –
CI, confidence interval; DFS, disease-free survival; ER, estrogen
receptor; NS, not significant; OS, overall survival; PgR, progesterone
receptor; RR, relative risk.
Figure 2
The 5-year overall survival (OS) after the first recurrence was 32.8%
(95% confidence interval [CI] 28.0–37.6%) for invasive lobular
carcinoma (ILC) and 26.7% (95% CI 25.3–28.0) for invasive ductal
carcinoma (IDC). The median survival after first recurrence was 22
months (range 0–115 months) for ILC versus 19 months (range
0–119 months) for IDC (P = 0.002).tributions of metastases were also different. Despite a
substantially less aggressive biologic phenotype, recur-
rence and survival were very similar between ILC and IDC
patients.
To our knowledge this is the largest published report on
ILC that comprehensively evaluates biologic characteris-
tics and clinical outcomes. The incidence of ILC observed
in the present study (8.2%) is in accordance with the inci-
dence range of 8–14% reported in the literature
[1,14,31–33]. In addition, the large number of patients,
the multi-institutional nature of the study population, and
the median follow-up period of more than 7 years
strengthen the reliability of the results and permit extrapo-
lation of the findings to routine clinical practice.
Clinical characteristics at diagnosis are different for ILC
than for IDC. Several studies showed that patients with
ILC are on average older at presentation than are IDC
patients [18,19,34]. Consistent with these data, in the
present study the median ages at diagnosis were
64.6 years for patients with ILC and 60.6 years for
patients with IDC. This older age at diagnosis in those
with ILC could be due to a low proliferative rate or greater
difficulties in detecting ILC. In terms of tumor size, 14% of
ILCs were found to exceed 5 cm as compared with only
9.1% of IDCs. The lack of a desmoplastic reaction may
make the lesion impalpable and invisible, both clinically
and mammographically, deferring the identification and
probably explaining why lobular carcinomas were larger at
diagnosis than IDCs. However, despite the slightly larger
size of ILCs, the rate of lymph node involvement was the
same in each group. The uniform appearance of bland
tumor cells that lack cellular atypia and often have a low
mitotic rate make the lobular carcinoma cells more difficult
to detect in metastatic lymph nodes. Thus, particular atten-
tion should be given to histologic examination of axillary
nodes in resection specimens of lobular carcinomas
because nodal metastases are more often missed with
ILCs, and false-negative results are more frequently
reported compared with ductal carcinomas [35].
From this report it is evident that the metastatic pattern for
ILC differs from that of IDC. ILC was less likely to affect
the lungs, pleura, and CNS than was IDC. By contrast, the
peritoneum, ovary, and gastrointestinal system were much
more likely to be involved in advanced ILC. Entries for gas-
trointestinal involvement in the database represent peri-
toneal and parenchymal involvement. CNS metastases
were more common with IDC. This database could not
clearly distinguish between brain, spinal cord, or lep-
tomeningeal metastases in its classification of CNS
involvement. It has been reported that ILC more often
involves the meninges and spinal fluid [13,36–38] but we
were unable to address this issue directly because of limi-
tations in the database. The factors that account for this
distinct metastatic pattern are unclear. The difference
could be due to a cell size or shape with physical proper-
ties that favor certain areas with microanatomy that is
more conducive to stopping or trapping these types of
cells. Alternatively, the microenvironment of the ovary or
peritoneum may provide growth and survival factors that
favor ILC cells over IDC cells. Additional molecular or bio-
logic differences might account for this peculiar pattern of
metastasis. It has been demonstrated that loss of expres-
sion of the cell–cell adhesion molecule E-cadherin in ILC
may decrease adhesiveness of cells and facilitate this type
of infiltration [19,39,40]. Indeed, the findings of this study
support a different molecular biology of ILC.
Bilateral involvement is reported to be 20–29% in lobular
carcinoma [10,12,16,41,42]. In our dataset the incidence of
contralateral breast cancer in women with ILC was nearly
double that in women with IDC. This finding could make a
compelling case for the use of tamoxifen to prevent con-
tralateral breast cancer in women with lobular primaries.
Because only a few small and scattered studies have
addressed the biologic features of ILC, one of the main
objectives of the present study was to characterize more
comprehensively its biologic phenotype. This report defini-
tively confirms and extends the findings of some previous
studies [11,12,17,43–45] indicating that lobular carcino-
mas are significantly more likely to be steroid receptor
positive than are IDCs. These results also demonstrate
that lobular carcinomas are more likely to have low
S-phase fractions and to be diploid. The evaluation of
S-phase fractions in ILC in other published series confirms
our findings [18,20,46]. Few reports have evaluated the
well studied growth factor receptors HER-2 and EGFR, or
the tumor suppressor gene p53 in ILC. In the present
analysis, no more than 5–10% of tumors classified by a
broad range of pathologists as ILC over-expressed EGFR
and/or HER-2. Positivity for p53 was found half as often in
ILC as in IDC. Only two small studies have analyzed these
molecules in ILC [47–49] and their results are similar to
those reported here. The 5–10% of patients who were
positive for HER-2 or EGFR, or who were p53 positive,
may not have been of the classic ILC subtype but possibly
a variant, such as those found in the pleomorphic or mixed
ILC–IDC categories. ILC subtypes have been reported to
have different biologic characteristics and clinical behavior
as compared with the classic subtype [50–52], but the dif-
ference has not found to be statistically significant, although
the number of patients included in the various studies is
small. Unfortunately, we were unable to subtype further
those tumors with lobular histology. More study is needed
on these specific subtypes. However, together these find-
ings suggest that ILC is biologically different from IDC.
In general, the management of patients in this study with
ILC was somewhat different from the management of
Breast Cancer Research    Vol 6 No 3 Arpino et al.
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to play a role in the choice of surgical procedure selected
[11,44,53,54]. This analysis suggested that ILC was
treated by mastectomy slightly more frequently than was
IDC. Although this tendency to favor mastectomy may be
related to factors specific to the patient and/or surgeon,
the choice for these procedures is also influenced by
pathologic findings. Indeed, the diminished fibrotic reac-
tion present in ILC makes it difficult for pathologists and
surgeons to determine the gross extent of the disease
during surgery, and to achieve tumor-free margins after a
limited excision. With respect to systemic therapy,
because lobular carcinomas are more frequently steroid
receptor positive tumors, as expected a greater proportion
of ILC patients than of IDC patients received adjuvant
endocrine therapy.
From previous studies the prognosis for ILC compared to
IDC is unclear. An important finding of the present large
study is that the 5-year OS of patients with ILC is not dif-
ferent from that of patients with IDC. Therefore, the fact
that ILC has more favorable prognostic factors does not
translate into a survival advantage for patients with ILC.
Although ILC is associated with a less aggressive pheno-
type, this is offset by lobular carcinoma being more diffi-
cult to detect early, either by clinical examination or
mammography. Furthermore, the reported higher rate of
false-negative lymph nodes by histologic examination in
lobular carcinomas could cause a general under-staging
of this histologic type at the time of surgery.
Multivariate analyses did not identify any prognostic differ-
ences associated with ILC or IDC. In these analyses, con-
sidering all ILC and IDC patients together, lymph nodes
status, tumor size, age, S-phase, PgR status, and ER
status were found to be associated with both recurrence
and survival, but histology was not an important indepen-
dent predictor of recurrence or survival. Furthermore, the
same standard prognostic factors (tumor size, axillary
nodal status, hormone receptors, S-phase, and age) used
in ductal carcinoma are applicable in lobular carcinoma as
well [55].
Conclusion
Results from this large dataset show clearly that ILC and
IDC are different entities with different clinical courses and
different biologic phenotypes, but no clinically meaningful
differences in survival are evident. At present, both types
of breast cancer should be managed similarly and histo-
logic subtype (lobular or ductal) should not be a factor in
the therapeutic decision-making process, and should not
be considered an important prognostic or predictive factor
at diagnosis. Emerging technologies such as high
throughput genome mapping and microchip cDNA
expression arrays may further elucidate molecular differ-
ences in these different types of breast cancer.
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